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Summary
Objectives: The incidence of invasive fungal infections has increased considerably in recent
years. The aim of this study was to present a suitable early diagnostic procedure in immuno-
compromised patients, using a molecular assay.
Methods: From September 2005 to January 2007, 310 immunosuppressed patients were
followed for fungal infections for a 6-month period. EDTA-anticoagulant whole blood speci-
mens were collected prospectively once per week and stored at 20 8C until use in molecular
assays.
Results: Molecular assays were positive in 55 (17.7%) patients. The etiologic agents were
Candida albicans (67.3%), Aspergillus flavus (20.0%), Aspergillus fumigatus (7.3%), Candida
tropicalis (3.6%), and Candida krusei (1.8%). The sensitivity, specificity, and positive and
negative predictive values of PCR—ELISA with proven and probable invasive fungal infections
were 84.6%, 92.7%, 75.3%, and 95.8%, respectively. The results showed that the mean clinical
manifestation time was 38.96 days and the mean time of positivity of the molecular test (time
of infection) was 17.69 days. A linear model for predicted infection and clinical manifestation
time was found to be as follows: Y = 11.64 + 1.147X, r2 = 0.812, where Y is the time at
presentation of clinical signs and X is the time of infection (positive PCR—ELISA result).* Corresponding author. Tel.: +98 711 62920/21; fax: +98 711 6287071.
E-mail address: Badieep@yahoo.com (P. Badiee).
1201-9712/$36.00 # 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ijid.2008.04.011
Conclusion: It may be concluded that the molecular assay would help in the diagnosis of invasive
fungal infections at the early stage of infection, before clinical manifestations.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The incidence of invasive fungal infections (IFIs) has
increased considerably in recent years because of the
increasing population with HIV infection, transplant recipi-
ents, cancer patients, and other individuals receiving immu-
nosuppressive treatments. Among patients undergoing
transplants or treatment for malignancies, more intensive
regimens have resulted in more profound levels of immuno-
suppression for longer periods, and IFIs are more common in
these patients. The prevalence of IFIs ranges from 5% to 50%
in kidney and liver transplants,1 and in neutropenic patients
these infections are the major causes of morbidity and
mortality.2 Candida spp and Aspergillus spp are responsible
for more than 80% of all fungal infections in solid organ
transplant recipients.1 Survival of patients from such life-
threatening infections depends on early diagnosis, but clin-
ical manifestations of IFIs are nonspecific, and laboratory
methods are often unable to diagnose the infection in its
early stages.
The laboratory diagnosis of invasive mycoses involves one
ormore of threemethods, including isolation of the fungus by
culture, serological detection of antibody, antigen, or meta-
bolites from the fungus, and histopathological evidence of
invasion.3 Unfortunately, the diagnosis of IFIs remains diffi-
cult, and is sometimes only confirmed late, by biopsy; this
late on, most patients are too ill to undergo a biopsy.
Pathogenic fungi may require 2—3 weeks or longer in terms
of growing times. The detection of galactomannan antigen in
serum by enzyme immunoassay has been an important
adjunct in the diagnosis of invasive aspergillosis. Although
this test is promising as a screening tool, the effect on
specificity of a newly introduced lower positive cut-off value
is still under investigation.4
Various researchers have reported methods for the mole-
cular identification of fungal infections.5—9 A PCR assay for
detection of fungal nucleic acids may be the optimal diag-
nostic approach because it offers the potential of: (1) being
more sensitive than current culture-based methods, (2)
encompassing multiple fungal genera, and (3) being applied
to a variety of specimen types.10
The aim of this study was to present a suitable early
diagnostic procedure in immunocompromised patients by
molecular assay.
Materials and methods
This study was a cross-sectional investigation carried out with
immunocompromised patients. Previous studies1,11,12 have
revealed the incidence of IFIs among solid organ recipients
and neutropenic cases to be 5—50% (mean 25%). We con-
ducted the study on 310 cases to raise the confidence interval
to 95%.
From September 2005 to January 2007, recipients who
underwent transplantation at the Organ Transplant Unit(kidney and renal transplants) and leukemia patients with
neutropenia receiving chemotherapy at the Oncology Unit of
Nemazi Hospital affiliated to Shiraz University of Medical
Sciences in Southern Iran, were followed for fungal infections
for at least a 6-month period.
Upon admission to the hospital, all patients were evalu-
ated for any fungal colonization by providing swabs from the
mouth and vaginal and rectal tissues. Midstream urine sam-
ples were centrifuged for 10 min at 2500 rpm and were then
cultured on Sabouraud—dextrose agar (Merck, Darmstadt,
Germany). Colonization was defined as the presence of
fungus in one or more surveillance cultures in the absence
of local or systemic symptoms or signs of infection.13 Once
the patient had received graft or chemotherapy, they were
then entered into our study.
Liver transplant recipients received fluconazole (400 mg/
day) for 21 days after transplantation, and other patients did
not have any antifungal prophylaxis. We defined ‘time of
infection’ as the time at which there was presence of fungal
nucleic acid in the blood with no clinical signs. At this stage,
the number of fungal organisms is very low and no spread,
replacement, or affecting of other organs has occurred. We
defined the ‘clinical manifestation time’ as the time when
the fungal infection appears in the organs and damages them.
Unfortunately, the existing anti-fungal drugs are not effec-
tive enough against the infection at this stage of disease. The
infection time and time of clinical manifestation are mea-
sured in terms of days following the immunodeficiency con-
dition, that is, when the patients underwent organ
transplantation or chemotherapy.
During the follow-up, whenever the patients developed
fever after 96 hours of antibiotic therapy, or presented
radiological or mycological evidence of IFIs, the clinician
suspected a fungal infection. Clinical samples (consisting of
biopsy, urine, cerebrospinal fluid, pleural and abdominal
tap, bronchoalveolar lavage, and sputum) from these
patients were examined for fungal infection. All samples
were cultured on Sabouraud—dextrose agar, and direct
microscopic examination was also performed. Histological
study was performed for patients when a biopsy specimen
was taken by the clinician. Blood samples were cultured by
bedside inoculation onto BACTEC medium (Becton—Dickin-
son, Sparks, MD, USA).
Four milliliters of ethylenediaminetetraacetic acid
(EDTA)-anticoagulant whole blood specimens were collected
prospectively once per week and stored at 20 8C for PCR—
ELISA analysis. Erythrocytes, leukocytes, and fungal cell
walls were lysed according to van Burik et al.10 For sphero-
blast lyses, protein precipitation, and elution of DNA, QIAmp
DNA minikits (Qiagen, Hilden, Germany) were used in accor-
dance with the manufacturer’s recommendations. The opti-
cal densities of DNA solutions were measured at 260 nm for
DNA and 280 nm for proteins (Pharmacia Biotech, Ultrosco-
pec 3000, UV/visible spectrophotometer, Cambridge, UK).
Amplification and agarose gel electrophoresis were per-
formed as previously described.10 All primers and probes
Table 1 Primer and probes used for identifying fungi by PCR—ELISA
Primer or probe Nucleotide sequence (50 to 30) Ref. Chemistry and location
Primers
ITS1 TCC GTA GGT GAA CCT GC G G 14 18S rDNA universal fungal 50
primer
ITS4 TCC TCC GCT TAT TGA TAT GC 14 28S rDNA universal fungal 30 primer
Probes
ITS3 GCA TCG ATG AAG AAC GCA GC 14 50-end-labeled biotin probe
universal probe
AFLA GAA CGC AAA TCA ATC TTT 15 50-end-labeled digoxigenin probe;
ITS2 region of A. flavus
AFUM CCG ACA CCC ATC TTT ATT 15 50-end-labeled digoxigenin probe;
ITS2 region of A. fumigatus
ANIG GAC GTT ATC CAA CCA TTT 15 50-end-labeled digoxigenin probe;
ITS2 region of A. niger
ATER GCA TTT ATT TGC AAC TTG 15 50-end-labeled digoxigenin probe;
ITS2 region of A. terreus
ASPEN-G CCT CGA GCG TAT GGG GCT 15 50-end-labeled digoxigenin probe;
ITS2 region of Aspergillus and
Penicillium spp
CA AT TGC TTG CGG CGG TAA CGT CC 16 50-end-labeled digoxigenin probe;
ITS region of C. albicans
CT AA CGC TTA TTT TGC TAG TGG CC 16 50-end-labeled digoxigenin probe;
ITS region of C. tropicalis
CP AC AAA CTC CAA AAC TTC TTC CA 16 50-end-labeled digoxigenin probe;
ITS region of C. parapsilosis
CK GG CCC GAG CGA ACT AGA CTT TT 16 50-end-labeled digoxigenin probe;
ITS region of C. krusei
PCR—ELISA, polymerase chain reaction—enzyme-linked immunosorbent assay; ITS, internal transcribed spacer; AFLA, Aspergillus flavus;
AFUM, Aspergillus fumigatus; ANIG, Aspergillus niger; ATER, Aspergillus terreus; ASPEN-G, Aspergillus universal probe; CA, Candida
albicans; CT, Candida tropicalis; CP, Candida parapsilosis; CK, Candida krusei.
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listed in Table 1.14,15,16
To determine the sensitivity and to limit the assay to
fungal pathogens in the blood, suspensions of EDTA-antic-
oagulated blood samples with Candida (Candida albicans and
Candida tropicalis) and Aspergillus (Aspergillus flavus and
Aspergillus fumigatus) conidia (1—105 conidia/ml) were
diluted and removed for DNA extraction and amplification.17
Human DNA can obscure the detection of weak fungal DNA
bands on agarose gels,9 and the sensitivity of PCR—ELISA is
10—100 times that of ethidium bromide for monitoring DNA in
blood samples. The collection of blood samples was per-
formed on a weekly basis, during the first few weeks of
infection, whenever the result of ethidium bromide for
monitoring DNA was weak; this method was used for mon-
itoring of DNA in samples with weak fungal DNA and for
identification of species that are pathogens in humans.
To identify species of pathogenic fungi, another oligonu-
cleotide (ITS3 universal probe) was used with specific probes
of fungi as internal capture probes in the PCR—ELISA. This
oligonucleotide was biotin labeled at the 50 end. The PCR—
ELISA was performed according to the manufacturer (PCR—
ELISA DIG Detection Roche, Mannheim, Germany).
IFIs were defined as ‘proven’ or ‘probable’ as per the
criteria proposed by the European Organization on Research
and Treatment in Cancer and the Mycoses Study Group(EORTC/MSG).18 The date of a proven diagnosis was the
day on which the positive histopathological sample was
obtained. The date of a probable diagnosis was defined as
the day on which the sample that yielded fungi in culture was
obtained. The date of a possible diagnosis was defined as the
day of onset of clinical symptoms. PCR—ELISA precocity in
diagnosing Systemic Candidiasis (SC) was assessed in compar-
ison with the timing of the clinical suspicion of infection, the
results of computed tomography (CT), and histological and
microbiological criteria as defined by the EORTC/MSG.18,19
Following examination of all of the collected weekly blood
samples from the 310 patients (7380 samples), patients who
neither developed clinical signs of IFIs nor received empirical
antifungal therapy as proposed by EORTC/MSG were taken to
be ‘controls’; the remainder were our ‘subjects’.
The algorithm for the diagnosis of IFIs is described in
Einsele et al.9 Data were analyzed using the Chi-square test,
post-hoc test, paired t-test, and regression stepwise test.
Results
Of the 409 patients who were admitted to the hospital
between September 2005 and January 2007, 310 (120 renal
recipients, 48 liver recipients, and 142 leukemic patients)
entered our study and were followed for 6 months. The
remaining 99 subjects were excluded, due to their failure
Figure 1 Relationship between time of infection and time of
clinical signs by linear, cubic, and quadratic model.
Table 2 Sites of body colonized with Candida spp
Site of isolate Kidney recipients
Frequency (%)
Mouth 109 35.2
Vagina 8 2.6
Urine 3 0.9
Mouth/vagina 29 9.4
Mouth/rectal swab 18 5.8
Mouth/urine 1 0.3
Mouth/vagina/rectum 10 3.2
Without colonization 132 42.6
Total 310 100.0
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did not attend for the follow-up was excluded from the
study). The female-to-male ratio was 120:190. The mean
age of recipients was 33.6 years (range 3—73 years), mean
hospitalization time was 23.8 days (range 14—150 days), and
178 patients (57.4%) had Candida colonization in different
sites of their bodies on entering the study (Table 2). There
was significant correlation between hospitalization time and
IFIs. Also, we noticed a significant correlation between fungal
colonization and IFIs ( p < 0.001).
Clinical samples were examined for fungal infections by
routine methods (direct examination and fungal culture),
and 33 (10.6%) patients had positive cultures for fungal
infections. Isolated fungi were C. albicans (57.6%), A. flavus
(24.2%), A. fumigatus (6.1%), Mucor (3.0%), and Alternaria
spp (9.1%). Five patients with IFIs had a positive blood culture
result for C. albicans.
The lower limit of detection of the PCR assaywas 2 cfu/ml of
whole blood. For sensitivity and specificity of molecular assays,
blood samples from the patients who neither developed clini-
cal signs of IFIs nor received empirical antifungal treatment
were examined, and 18 patients had positive PCR results for
Candida spp and Aspergillus spp (false-positive test results).
The sensitivity, specificity, and positive and negative predic-
tive values of PCR—ELISA in our study with proven and probable
IFIs were 84.6%, 92.7%, 75.3%, and 95.8%, respectively.
Molecular assays (panfungal PCR and PCR—ELISA) were
positive in 55 (17.7%) patients. Fifteen patients had proven
IFIs (histopathological evidence of severe esophagitis, inva-
sive sinusitis, and central nervous system infection), 18
patients were probable (pneumonia with positive culture
from bronchoalveolar lavage and bronchial washing with
clinical and radiological criteria, abdominal magnetic reso-
nance imaging showing abscess in the liver, positive culture
from clinical specimens and related clinical signs), and 22
patients were possible (with clinical signs of infection), as per
EORTC/MSG. The etiologic agents found with the molecular
assay were C. albicans (67.3%), A. flavus (20.0%), A. fumi-
gatus (7.3%), C. tropicalis (3.6%), and Candida krusei (1.8%).
All patients with a positive fungal culture were also positive
by PCR, except for one patient who was found with Mucor on
histopathological examination.
Of 310 patients, 54 died; of the patients who died, 35
patients had IFIs. As our statistical analysis shows, there is asignificant correlation between IFIs and patient death
( p < 0.0001). Patients who were on fluconazole prophylaxis
exhibited symptoms later than those who were not.
The relationship between the time of clinical manifesta-
tion and time of positivity of molecular test (as previously
defined) was evaluated using the paired t-test. Results
showed that the mean clinical manifestation time was
38.96 days (standard deviation (SD) 33.44) and the mean
time of positivity of molecular test (time of infection) was
17.69 days (SD 17.18). The difference is significant
( p < 0.001), and the mean difference was 21.27 days with
an SD of 28.12, d.f. = 5, and t = 5.45.
To investigate the influential factor in the time of appear-
ance of the infection, regression stepwise analysis was used.
This study shows that providing all conditions are constant,
cases with fungal colonization exhibited clinical signs 5.7
days earlier than non-colonized patients. Longer hospitaliza-
tion resulted in earlier clinical manifestation, while use of
prophylactic anti-fungal drugs did not prevent the manifes-
tation of clinical signs and just delayed them. Investigation of
the organs revealed that cases with lung and sinus infections
exhibited clinical signs at the same time after positivity of
PCR—ELISA, whereas, those with gastrointestinal infections
showed the signs later.
Linear, quadratic, and cubic models for predicted infec-
tion time and clinical manifestation time are shown in
Figure 1 and as follows:
Linear model : Y ¼ 11:64þ 1:147X; r2 ¼ 0:812;
Quadratic model :Y ¼ 9:17þ 1:37X  0:0025X2;
r2 ¼ 0:815;
Cubic model : Y ¼10:56þ 1:17X þ 0:003X2
 4 105X3; r2 ¼ 0:816;
where X = time of infection and Y = time of clinical signs.
In patients who were treated with anti-fungal agents, if
the treatment was successful, the fungal PCR assay became
negative after 14 days, and if the treatment failed, PCR—
ELISA was positive until death.
Table 3 Predicted time for the manifestation of clinical signs
after positive PCR—ELISA
X 1 7 14 21 28
Y
10—17 *
18—25 *
26—33 *
34—41 *
42—49 *
X = time at positive PCR—ELISA; Y = time at presentation with clinical
signs.
*Positive PCR—ELISA on X and clinical manifestation times on Y as
calculated by linear model.
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IFIs remain a significant cause of morbidity and mortality in
immunocompromised patients. The most important para-
meter in determining the success of therapy for IFIs in these
patients is the rapidity with which the diagnosis is made and
treatment is initiated.
In immunocompromised patients, colonization of mucosal
surfaces by endogenous Candida species is often followed by
invasion of the vascular space, which carries a high risk of
disseminated candidiasis. Candida colonization was observed
in 57.4% of the total patients and 90% of the PCR-positive
patients in this study. Preparing cultures of patient clinical
samples is not a sensitive method for proper diagnosis, and in
some infections such as chronic disseminated candidiasis
(hepatosplenic candidiasis) supporting microbiological cri-
teria are not required for the ‘probable’ category.18 In this
study, blood culture was positive in five patients. Detection
of fungemia by means of fungal blood cultures is notoriously
difficult and IFIs are diagnosed only at autopsy. However, it is
possible that naked DNA be detected by PCR due to the
presence of dead and degrading fungi within circulating
phagocytes.20
In this study whole blood was used for DNA extraction
from patients. The use of EDTA-whole blood samples
allows for the detection of circulating conidia, spores,
and hyphal fragments that have found their way into the
blood stream.10 As the volumes of serum used for DNA
extraction tend to be smaller than the high volumes of
whole blood, the sensitivity of the assay due to the lower
fungal yield may decrease,9 and the sensitivity of PCR in
plasma is lower than that of the PCR performed on a whole
blood sample.21
Morace et al. reported that molecular methods are sig-
nificantly more sensitive than conventional fungal blood
cultures and have a high negative predictive value (97.5%)
for the development of disseminated candidiasis in neutro-
penic patients.22
Florent et al., on the basis of the analysis of 1205 serum
samples from 167 patients, found that the sensitivity, spe-
cificity, and positive and negative predictive values of the
PCR—ELISA for proven and probable invasive aspergillosis
cases were 63.6%, 89.7%, 63.6%, and 89.7%, respectively,
when samples with two consecutive positive results were
used.19 Other studies have recognized PCR—ELISA as a usefuldiagnostic tool for the detection and identification of fungal
infections.23,24 Comparing the results of this study with
previously reported ones,22—24 we found that the PCR—ELISA
sensitivity and specificity values are within the same range.
Unlike in other studies19,9,25 that reported that if a person
had Candida colonization, molecular assay is not positive, in
our study there were 10 patients with Candida colonization
who had positive PCR—ELISA for C. albicans, and in follow-up
they did not exhibit any clinical signs. This difference may be
due to transient candidiasis in these patients or the very
limited number of patients in previous studies.
The priority use of PCR over that of clinical and radiolo-
gical signs has also been reported in other studies.9,26 Hebart
et al. reported PCR as the earliest indicator of invasive fungal
infections, preceding clinical evidence with a mean of 5.75
days (range 0—14) in febrile neutropenic patients.26 Florent
et al. reported that PCR—ELISA positivity preceded mycolo-
gical/histological diagnosis in eight patients (a total of 12
patients who had mycological/histological diagnoses) over a
range of 1—110 days and preceded abnormalities on CT scan
in 19 patients over a range of 1—84 days.19 In our study, PCR-
positive results were obtained within 21.27 days prior to the
manifestation of clinical signs. This gap may be related to the
different types of immunosuppressive drugs used, number of
white blood cells (WBC count), and human cytomegalovirus
infection. It is important to note that recovery from fungal
infections is often primarily related to an improvement in the
patient’s neutrophils.
In this study, 63.6% of patients with IFIs died without any
autopsy. We did not know if the patient deaths were due only
to the progression of their background diseases or to the
fungal infections, but we believe that if diagnosis and treat-
ment are carried out as early as possible, the number of
deaths will fall. In patients treated with antifungal therapy,
the fungal PCR assay became negative after 14 days if the
treatment was successful, and PCR—ELISA was positive until
death if treatment failed.
To predict the manifestation of clinical signs by a linear
model, we can draw a table (Table 3). According to this
table if, for example, PCR was positive on day 1, clinical
signs would appear within 10—17 days, or if PCR was
positive on day 7, clinical signs would appear within 18—
25 days. Since patients do not respond to treatment fol-
lowing a late diagnosis of fungal infection, and as even in
some cases they have died, the need for an effective
procedure for early diagnosis is urgent. This has been
the goal of our study, which may make a contribution to
the development of more efficient methods for the early
diagnosis of IFIs. Further investigation into this matter is
warranted.
Conclusions
It may be concluded that molecular assays could help to
diagnose IFIs in the early stages of infection, preceding
clinical manifestation. Immunocompromised patients at high
risk should be checked weekly by this method for the early
diagnosis of fungal infections. This method can also provide
greater confidence in excluding a diagnosis of IFIs when
negative results are obtained, and this method could be used
for the monitoring of treatment, as well.
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